Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
RESEARCH TRIANGLE PARK, N.C., June 15 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics announced today that it has agreed to a co-promotion arrangement with Novartis Vaccines to jointly market and sell their respective post-exposure rabies products.
Talecris provides HyperRAB® S/D (Rabies Immune Globulin [Human]), an essential component of rabies post-exposure prophylaxis for previously unvaccinated individuals, that is administered in combination with rabies vaccines. Novartis provides RabAvert® Rabies Vaccine for both pre-exposure and post-exposure prophylaxis.
"Through our agreement with Novartis, we are seeking to improve access to this critical-care therapy by ensuring that patients receive the immune protection provided by HyperRAB S/D and RabAvert," said John Perkins, executive vice president, global commercial operations at Talecris. "By co-promoting the two products, we will also enhance awareness of the recommended CDC guidelines for preventing rabies following an exposure."
Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. Rabies has the highest case fatality rate of any known infectious disease and is virtually 100% fatal following onset of clinical symptoms. The rabies virus  infects the central nervous system, ultimately causing disease in the brain followed by death. For people who have not been vaccinated against rabies previously, post-exposure anti-rabies vaccination should always include administration of both passive antibodi